At 44 years old, I was ready to hit the reset button. In March of 2025, my partner and I stepped away from our careers. The decision wasn’t reckless, it…
Editor's Note: This article was shared with Patient Worthy by our friends at Elephants & Tea. It was originally written by Jenny Gomez, a breast cancer survivor. To see the…
Editor's Note: The above photograph is credited to Patient Voice. “Ringing the bell” is an enduring image associated with cancer survivorship. It represents victory, celebration and the end of treatment.…
As reported by Bioengineer, new insights published by Nastoupil L.J. in Nature Reviews Clinical Oncology (2026) highlight an important evolution in the management of relapsed or refractory follicular lymphoma (FL).…
In a recent statement by AstraZeneca, AstraZeneca and Daiichi Sankyo’s antibody‑drug conjugate Datroway (datopotamab deruxtecan) has been granted Priority Review by the U.S. Food and Drug Administration (FDA) for use…
A trio of Swiss biotechnology companies is advancing diverse therapeutic pipelines, with recent developments spanning inflammatory skin disease, immune‑mediated hair loss, and hard‑to‑treat cancers. Together, these milestones highlight how distinct…
Scientists find polymer-coated nanoparticles together with therapeutic drugs offer promise for cancer treatment, including treatment for ovarian cancer. According to Science Daily, these nanoparticles may be targeted to tumors where…
As reported on ScienceDaily, a research team at the Icahn School of Medicine at Mount Sinai has unveiled a novel immunotherapy that tackles metastatic cancer by attacking the tumor’s protective…
Editor's Note: Patient Worthy is honored to share this patient story, provided to us by our friends at Heal Canada, and originally written for the National Post. James, 73, is…
The European Medicines Agency (EMA) has issued a positive opinion recommending that retifanlimab (Zynyz) be approved for an expanded indication to treat adults with advanced squamous cell carcinoma of the…
As reported on Science Daily, a breast cancer vaccine tested more than 20 years ago is drawing renewed scientific interest after researchers discovered that every participant in the original trial…
Cancer immunotherapy represents one of modern medicine's greatest achievements, yet it's also one of its most frustrating paradoxes: a treatment that works miracles for some patients fails silently for others.…
Osteosarcoma is a diagnosis no family should ever have to face. It is the most common primary bone cancer in children and adolescents, yet treatment options have hardly changed in…
Twenty years is a long time to believe a cancer chapter has closed. For two decades after my radical prostatectomy, I lived with the quiet confidence of someone who had…
As reported on Business Wire, ImmunityBio has released new clinical findings suggesting that its interleukin‑15 superagonist, ANKTIVA® (nogapendekin alfa inbakicept), may help restore immune function and improve survival outcomes in…
As reported on PharmaBiz, AstraZeneca’s phase III LATIFY trial has fallen short of its primary objective, with the combination of the ATR inhibitor ceralasertib and the PD‑L1 inhibitor Imfinzi (durvalumab)…
Editor's Note: Patient Worthy is proud to share this story from our friends at Elephants & Tea. To see the story in its original format, please click here. “Well, good…
Editor's Note: Patient Worthy is proud to share this article, originally written by Katie Tat, from our friends at Elephants & Tea. To see the article in its original format,…
As reported on Science Daily, a groundbreaking study suggests that customizing breast cancer screening based on individual risk factors may outperform the traditional one-size-fits-all approach of annual mammograms. The research,…
In a recent statement, the U.S. Food and Drug Administration (FDA) has authorized regular approval to rucaparib (Rubraca) for adults with metastatic castration-resistant prostate cancer (mCRPC) harboring deleterious BRCA mutations—either…
Incyte has announced encouraging top-line findings from its pivotal Phase III frontMIND trial, evaluating tafasitamab (marketed as Monjuvi/Minjuvi) in combination with lenalidomide and the standard R-CHOP regimen for newly diagnosed…
As reported on FiercePharma, Johnson & Johnson has secured a significant milestone in prostate cancer treatment with the FDA’s approval of Akeega for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer…
Editor's Note: This poem, originally written by Spence Shishido, was shared with Patient Worthy by our friends at Elephants & Tea. To see the poem in its original format, please…
As reported on BioPharmaDive, new clinical trial data presented at the American Society of Hematology (ASH) annual meeting suggests that an early treatment regimen combining Tecvayli (Johnson & Johnson’s bispecific…
As reported on NPR, Tatiana Schlossberg, journalist and granddaughter of former U.S. President John F. Kennedy, has disclosed that she is battling a rare and aggressive form of leukemia. In…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
